Skip to main content
Sartorius Stedim Biotech logo

Sartorius Stedim Biotech — Investor Relations & Filings

Ticker · DIM ISIN · FR0013154002 LEI · 52990006IVXY7GCSSR39 PA Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2025-08-04 Declaration of Voting R…
Country FR France
Listing PA DIM

About Sartorius Stedim Biotech

https://www.sartorius.com/en

Sartorius Stedim Biotech is a leading international provider of equipment and services for the biopharmaceutical industry. The company offers integrated solutions that support the entire lifecycle of drug development and manufacturing, from research and development to quality assurance and commercial production. Its comprehensive portfolio includes technologies for filtration, fluid management, fermentation, cell culture, and purification. Key products encompass bioreactors, single-use systems, process filtration equipment, cell culture media, and data analytics software. Sartorius Stedim Biotech enables its customers to develop and manufacture biotech medications, including cell and gene therapies, more efficiently and safely, helping to accelerate the translation of scientific discoveries into patient care.

Recent filings

Filing Released Lang Actions
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a regulatory announcement from Sartorius Stedim Biotech SA regarding the total number of shares and voting rights as of July 31, 2025. This type of disclosure is a standard regulatory requirement under French law (Article L 233-8-II of the Code of commerce). While it relates to share capital, it is a periodic regulatory disclosure of voting rights rather than a specific transaction in own shares (POS) or a major shareholding notification (MRQ). As it is a standard regulatory filing that does not fit into the more specific categories like dividend announcements or management changes, it is best classified as a Regulatory Filing (RNS).
2025-08-04 English
Sartorius Stedim Biotech SA: Communiqué de mise à disposition de documents
Report Publication Announcement Classification · 1% confidence The document is a short press release (1626 characters) titled 'Communiqué de mise à disposition de documents' (Announcement of availability of documents). It informs investors that the first-half 2025 results and consolidated accounts are available via a provided URL. Per the 'Menu vs Meal' rule, since this is an announcement of a report's availability rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-07-22 French
Sartorius Stedim Biotech SA: Information on Document Availability
Report Publication Announcement Classification · 1% confidence The document is a short press release (1461 characters) that explicitly states it is providing 'Information on Document Availability' for the first half 2025 results. It directs the reader to a URL to access the actual report. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2025-07-22 English
Sartorius Stedim Biotech SA: Information on Document Availability
Report Publication Announcement Classification · 1% confidence The document is titled "Sartorius Stedim Biotech SA: Information on Document Availability" and explicitly states that the "report on the first half 2025 results" is now available, providing a link to the report. The document length is short (3133 characters), and the content focuses on announcing the availability of a report rather than containing the report itself. The AMF Category listed is "Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report." This structure strongly indicates an announcement about a report's publication, not the comprehensive report (which would be an IR or AR). Therefore, it fits the definition of a Report Publication Announcement (RPA).
2025-07-22 English
First-Half Financial Report January to June 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'First-Half Financial Report' for the period January to June 2025. It contains comprehensive financial statements, including sales revenue, EBITDA, balance sheet data, cash flow analysis, and employee metrics. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-07-22 English
Rapport financier semestriel de janvier à juin 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Rapport financier semestriel de janvier à juin 2025' (Semi-annual financial report from January to June 2025) for Sartorius Stedim Biotech. It contains detailed financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance for the first half of the year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-07-22 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.